569224-U
Discovery® C18 (5 µm) HPLC Columns
L × I.D. 25 cm × 10 mm, HPLC Column
Synonym(s):
Discovery RP18 HPLC Column
Sign In to View Organizational & Contract Pricing.
Select a Size
All Photos(1)
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
Product Name
Discovery® C18 HPLC Column, 5 μm particle size, L × I.D. 25 cm × 10 mm
material
stainless steel column
agency
suitable for USP L1
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
12% Carbon loading
parameter
≤70 °C temp. range
400 bar pressure (5801 psi)
technique(s)
HPLC: suitable
LC/MS: suitable
L × I.D.
25 cm × 10 mm
surface area
300 m2/g
surface coverage
3 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical particle platform
fully porous particle
matrix active group
C18 (octadecyl) phase
particle size
5 μm
pore size
180 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
- Development and Validation of a Reversed-Phase HPLC Method with UV Detection for the Determination of L-Dopa in Vicia faba L. Broad Beans.: Highlights the application of the Discovery® C18 HPLC Column in developing a method for the accurate quantification of L-Dopa in natural sources, which is essential for studies in neuropharmacology and natural product research (Tesoro et al., 2022).
- Simultaneous estimation of paclitaxel and erlotinib in plasma by liquid chromatography/(+) electrospray tandem mass spectrometry: application in formulation development and pharmacokinetics.: This study employs the Discovery® C18 HPLC Column to enhance the simultaneous analysis of paclitaxel and erlotinib, critical for cancer therapy research and formulation development (Khuroo et al., 2022).
Features and Benefits
- Excellent reproducibility
- Exceptional peak shape for basic and acidic analytes
- Stable, low-bleed LC-MS separations
- Separation of peptides and small proteins
- Lower hydrophobicity than many comparable C18 columns, providing faster analysis
General description
Use Discovery® C18 for any method that specifies a C18. The exceptional peak shape, reproducibility, and stability make it the column of choice for all C18 methods from demanding to routine.
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
T R Shantha Kumar et al.
Journal of pharmaceutical and biomedical analysis, 38(1), 173-179 (2005-05-24)
A simple, precise and accurate isocratic reverse-phase liquid chromatography method with programmed wavelength detection has been validated to quantify DRF-4367 and Phenol red, simultaneously for application in rat in situ single pass intestinal perfusion study to assess intestinal permeability of
Ramisetti Nageswara Rao et al.
Journal of separation science, 32(9), 1312-1322 (2009-04-29)
Modafinil, adrafinil and their related substances were synthesized and analyzed by RP-LC with ESI-MS/MS. The ionization mode, polarity, cone voltage, and chromatographic conditions were evaluated. The optimum LC-MS conditions to obtain fragment ions indispensable for identification of the structures were
Himal Paudel Chhetri et al.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 22(5), 483-487 (2014-12-05)
This study presents the optimization of a simple HPLC-UV method for the determination of metformin in human plasma. Ion pair separation followed by UV detection was performed on deproteinized human plasma samples. The separation was carried out on a Discovery
Abbas Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(24), 2423-2429 (2011-07-26)
A novel isocratic reversed-phase high performance liquid-chromatography/ultraviolet detection method for simultaneous determination of cefdinir and cefixime in human plasma was developed and validated after optimization of various chromatographic conditions and other experimental parameters. Sample preparation based on a simple extraction
Sheelendra Pratap Singh et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(27), 2845-2851 (2011-09-06)
Tamoxifen is the agent of choice for the treatment of estrogen receptor-positive breast cancer. Tamoxifen is a substrate of P-glycoprotein (P-gp) and microsomal cytochrome P450 (CYP) 3A, and biochanin A (BCA) is an inhibitor of P-gp and CYP3A. Hence, it
Related Content
General Care and Use of Supelco™ HPLC Columns
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service